ReviewPalliative care and social practice2020
Midazolam: an essential palliative care drug.
Review in Palliative care and social practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Pooled it
- A randomized controlled clinical trial of intranasal versus subcutaneous midazolam for agitation in terminal illness (MinTU study).Palliative medicine · 2026Trial
- The effect of preoperative remimazolam application on emergence delirium in children under sevoflurane anesthesia based on electroencephalogram analysis: a randomized, double-blind, placebo-controlled study.BMC anesthesiology · 2026Trial
- Comparing Cognitive Recovery of Remimazolam versus Propofol in Elderly Patients Undergoing Colonoscopy: A Randomized Controlled Trial.Clinical interventions in aging · 2024Trial
- Longitudinal Cognitive Recovery After Critical Illness: Trajectories in Sepsis and Non-Sepsis Survivors.Journal of intensive care medicine · 2026Article
- Approach to subcutaneous infusions in primary care: Indications, practical considerations, acceptability, and tolerability.Canadian family physician Medecin de famille canadien · 2026Review
- Intranasal Diazepam Outperforms Midazolam and Lorazepam in Early Seizure Control in Pilocarpine-Induced Mice Model.Neurochemical research · 2026Article
- Continuous sedation in adolescent and young adult cancer patients under home-based end-of-life care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
- Clinical profile and challenges of midazolam-based palliative sedation for terminal cancer patients: A retrospective observational study from a tertiary medical center in mainland China.Palliative care and social practice · 2026Article
- Conceptual barriers to palliative sedation: insights from focus group interviews with specialist palliative care professionals.BMC palliative care · 2025Article
- Longitudinal Cognitive Recovery in Survivors of Critical Illness: Impact of Sepsis and Benzodiazepine Exposure.medRxiv : the preprint server for health sciences · 2025Article
- Effects of Midazolam and Dexmedetomidine on Cognitive Dysfunction Following Open-Heart Surgery: A Comprehensive Review.Brain and behavior · 2025Review
- Emergency palliative cancer care: anxiety and midazolam.BMC palliative care · 2025Article
- Review of the Interactions Between Anesthetic Agents and Chemotherapeutic Agents in Cancer Cell Lines Studied In Vitro.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- Remimazolam used for sedation during spinal anesthesia puncture provides faster sedation effect and increase recovery rate compared to midazolam: a randomized controlled trial.Frontiers in pharmacology · 2025Article
- A Comparative Evaluation of Midazolam, Ketamine and Their Combination as Sedative Agents in Pediatric Dentistry: A Systematic Review and Meta-analysis.Frontiers in dentistry · 2025Review
- Metabolite Measurement in Index Substrate Drug Interaction Studies: A Review of the Literature and Recent New Drug Application Reviews.Metabolites · 2024Review
- Fake Xanax: Designer Emerging Benzodiazepine Epidemic Linked to Morbidity and Mortality a Narrative Review.Neurology and therapy · 2024Review
- Midazolam Indications and Dosing in Palliative Medicine: Results from a Multinational Survey.Current oncology (Toronto, Ont.) · 2024Article
- Effect of Etomidate Versus Midazolam-Sodium Thiopental on Attenuating the Cardiovascular Response to Laryngoscopy and Tracheal Intubation.Anesthesiology and pain medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Midazolam is a commonly used benzodiazepine in palliative care and is considered one of the four essential drugs needed for the promotion of quality care in dying patients. Acting on the benzodiazepine receptor, it promotes the action of gamma-aminobutyric acid. Gamma-aminobutyric acid action promotes sedative, anxiolytic, and anticonvulsant properties. Midazolam has a faster onset and shorter duration of action than other benzodiazepines such as diazepam and lorazepam lending itself to greater flexibility in dosing than other benzodiazepines. The kidneys excrete midazolam and its active metabolite. Metabolism occurs in the liver by the P450 system. This article examines the pharmacology, pharmacodynamics, and clinical uses of midazolam in palliative care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.